From isotopes to advanced nuclear fuels: Paul Mann and Dr. Ryno Pretorius on The Next Big Thing

Published 1 October 2026

Mobeen Tahir
Director, Macroeconomics and Thematic Research

Key Takeaways

- ASP Isotopes (ASPI) operates across nuclear medicine, electronic gases, liquefied natural gas, and nuclear fuels. These four verticals are exposed to some of the most critical material supply gaps of the coming decade.
- The ASP technology traces back to South Africa's secret nuclear weapons programme and has been continuously refined since 1993, offering a proven, lower-cost alternative to conventional centrifuge enrichment.
- Modern reactor designs are engineered to be inherently safe. The physics of the system prevents meltdown without any need for human intervention.
- Russia controls more than 40% of global enrichment capacity. The US has banned Russian enriched uranium imports, but a Western alternative is still being built - making this a matter of energy security, not just economics.
- QLE has secured a 10-year, over $3 billion HALEU supply agreement with TerraPower and is advancing facilities across the US, South Africa, and the UK.

Nuclear energy is having a moment. Governments are committing to triple global capacity. Tech giants are signing 20-year power deals, and the race is on to build the fuel supply chains that will make it all possible. But isotope enrichment, the process at the heart of that supply chain, is dangerously concentrated, technically demanding, and poorly understood outside specialist circles.

Two companies are working to change that. ASP Isotopes (ASPI) is building enrichment infrastructure across nuclear medicine, semiconductors, and nuclear fuels. Its nuclear fuel subsidiary, Quantum Leap Energy (QLE), is focused specifically on producing the advanced fuels that next-generation reactors will need.

That is why we invited Paul Mann, founder and CEO of ASP Isotopes, and Dr. Ryno Pretorius, CEO of Quantum Leap Energy, onto The Next Big Thing. Paul came to this space from Wall Street, where his experience of supply chain fragility in the isotope sector ultimately led him to acquire and rebuild the

underlying technology. Ryno came from the engineering side, with a PhD in fluorination chemistry and years of hands-on experience scaling first-of-a-kind industrial processes.

This blog post summarises some of the key messages from the conversation. To get the full episode, follow the link here.

Why we spoke with ASP Isotopes and Quantum Leap Energy

ASP Isotopes is a holding in the WisdomTree Uranium and Nuclear Energy UCITS ETF (NCLR). The exchange-traded fund invests across the full value chain of the uranium and nuclear energy sector, spanning upstream producers, midstream processors, and innovators. ASP Isotopes is classified as an innovator within that framework, reflecting its proprietary enrichment technology and its exposure to multiple high-growth applications across nuclear medicine, semiconductors, and advanced reactor fuels.

What is ASP Isotopes?

Paul Mann founded ASPI after years managing money on Wall Street, where some of his most profitable short positions were companies whose operations were constrained by isotope supply chain problems. He began getting interested in critical materials around 2017, when he started to see clear cracks emerging in supply chains that had been stable for decades. About five years ago, he and his co-founder acquired technology assets in South Africa out of a business rescue process - essentially a form of bankruptcy - and have since raised around $400 million to build out the business. ASPI now operates across four verticals. In nuclear medicine, its PET1 Labs subsidiary is the leading supplier of nuclear medicine isotopes in South Africa and also operates radio pharmacies in the United States. In electronic gases, ASPI has built a plant to enrich silicon-28, the ultra-pure isotope required for next-generation semiconductors and quantum computing hardware; it has shipped its first samples and expects commercial products before the end of the year. The company is also bringing online a helium and liquefied natural gas facility, as helium is a material with no real substitute, used in semiconductor manufacturing and rocket launches, and supply from its traditional sources in Qatar and Russia has been shrinking. The fourth vertical is nuclear fuels, which is handled through QLE.

What is the ASP technology and where does it come from?

The aerodynamic separation process (ASP) is the technology at the heart of both ASPI and QLE. Its origins are extraordinary. In the 1970s and 1980s, South Africa secretly developed nuclear weapons, producing somewhere between six and seven warheads entirely without centrifuges. The approach they used was a vortex tube or aerodynamic separation process, which achieved weapons-grade uranium enrichment at a fraction of the cost of conventional centrifuge technology. When South Africa signed the Treaty of Pelindaba in 1993, making Africa a nuclear-weapons-free continent, all the hardware, licensing, and knowledge from the programme was preserved in place. The scientists who came out of it continued to develop and refine the technology. Ryno Pretorius, who has a PhD in fluorination chemistry funded by the South African government specifically to keep this expertise alive, is part of a small group of engineers who bridge the gap between the original post-retirement scientists and a new generation entering the field.

His journey to QLE took him through South Africa's Nuclear Energy Corporation, a period scaling hard tech startups in California (where he learned magnesium production, which is a key step in converting uranium hexafluoride into metal form), and ultimately a phone call to Paul Mann the day he got his green card. QLE now uses two enrichment technologies: the ASP process and a laser-based enrichment approach, giving it complementary tools for different isotopes and applications.

Why are new reactor designs inherently safer?

One of the most important parts of the conversation was Ryno's explanation of why modern reactor designs are fundamentally different from those associated with historic accidents. The Chernobyl reactor, he noted, was a knowingly flawed design even at the time: a graphite-moderated, water-cooled system where attempts to cool the reactor actually increased the nuclear reaction, rather than slowing it. New reactor designs work on the opposite principle: the more they heat up, the more the moderation naturally changes, and the reaction slows itself down. Reactors like the X-energy gas-cooled design and the TerraPower Natrium reactor are what engineers call 'inherently safe'. Engineers say they cannot melt down because the physics of their design prevents it, without any need for human intervention. Paul added that most modern reactors are largely autonomous, controlled by computers rather than operators. The highest standard of engineering safety is designing out the hazard entirely, rather than relying on someone to press the right button at the right moment. That is what this new generation of reactors achieves.

What is HALEU and why does it matter?

Most of today's nuclear reactors run on low-enriched uranium (LEU), enriched to below 5% uranium-235. The next generation of reactors, including small modular reactors and advanced designs from companies like TerraPower and X-energy, require high-assay low-enriched uranium, or HALEU, enriched to between 10% and 20%. HALEU enables longer fuel cycles, greater efficiency, and opens the door to extending the operational life of existing reactors that are currently destined for decommissioning. The challenge is that almost no Western enrichment capacity for HALEU currently exists. Russia has historically dominated global uranium enrichment, accounting for more than 40% of capacity. The US has already banned imports of Russian enriched uranium, but the domestic supply chain to replace it is still being built. US government estimates put the HALEU market at somewhere between 50 and 600 tonnes per year by 2035, and the current global nuclear fleet does not even have enough supply for its existing LEU requirements. QLE is one of the few companies building dedicated HALEU enrichment capacity, with facilities planned across the US, South Africa, and the UK.

What partnerships has QLE secured, and how does the commercial model work

The commercial logic for long-term nuclear fuel supply agreements mirrors what is driving the broader energy deals being signed by Microsoft, Meta, and others: reliable, stable baseload power is a competitive necessity for data centres, and the fuel supply chain that makes that possible needs to be locked in. QLE has secured a 10-year supply agreement with TerraPower, Bill Gates' nuclear venture, worth over $3 billion. TerraPower is also supporting QLE financially through the development and commercialisation of

the technology, as well as providing a committed offtake agreement that allows QLE to build out capacity with confidence. QLE is also in discussions with a major US utility (which has requested anonymity to protect commercially sensitive information) and is actively advancing plans with Fermi America for a potential HALEU enrichment and conversion facility at the Amarillo, Texas site. The Amarillo site already has decades of geological, environmental, and operational data available, which significantly accelerates the development timeline. The company is also engaged with European nuclear technology companies about future fuel deliveries. Ryno's description of the commercial dynamic was direct: the industry faces a chicken-and-egg problem where customers want supply agreements before they commit, but suppliers need committed offtake before they can justify the capital investment to build. Ryno said QLE is going all in regardless, because the demand signal is clear enough.

What is the regulatory and policy backdrop?

Ryno was recently in Washington DC, and his read of the policy environment was notably optimistic. Nuclear legislation is advancing rapidly, and he described it as moving on a near-weekly cycle. The two biggest obstacles to nuclear deployment, he argued, are the regulatory framework and the fuel cycle, and both are being addressed simultaneously. On the regulatory side, the Trump administration has targeted Nuclear Regulatory Commission (NRC) approval timelines of 18 months, compared to the 10 to 15 years that were normal under previous administrations. The pilot plant programme, supported by the Department of Energy and the Idaho National Laboratory, has already seen four reactors reach criticality, with a fifth done entirely by private funding. Oklo's isotope reactor going online in Lockhart, Texas, built in under a year, is the clearest signal yet that the pace of progress has genuinely changed. On the fuel cycle side, Ryno pointed to growing momentum around spent fuel recycling, alternative fuel sources including thorium and plutonium, and the development of domestic uranium mining capacity. The US has significant in-ground uranium resources that have been held back by regulatory and environmental constraints, and those constraints are now being revisited.

What is the geopolitical dimension of the nuclear fuel supply chain?

The geopolitical dimension of the nuclear fuel supply chain is something Paul and Ryno addressed directly. The world has committed to tripling nuclear capacity over the next 25 years or so, and 38 countries are at least discussing the target. But the supply chain to get there is deeply exposed. Kazakhstan is currently the world's largest producer of uranium yellow cake, a legacy of the Soviet era, and Ryno noted plainly that China is likely to buy as much of it as it can. That means the West needs to build its own supply from Africa, South America, Canada, and North America. The US itself has significant uranium resources, including some locations where uranium concentration in groundwater is high enough that it can be extracted without conventional mining. The enrichment side of the picture is even more concentrated: Russia's dominant share of global enrichment capacity means that even France, which has historically drawn uranium from African suppliers, could find itself dependent on Russian enriched product as those African supply routes are disrupted. Paul summarised the challenge clearly: the world does not just need more uranium in the ground. It needs the full supply chain: mining, conversion, enrichment, and deconversion, to be rebuilt at scale in the West. That is the opportunity ASPI and QLE are positioning themselves to fill.

Final thought

This conversation was a reminder that the nuclear energy story is not just about reactors. It is about the entire supply chain behind them, and right now that supply chain has serious gaps. Ryno was refreshingly blunt about why progress has been slow. We have spent decades applying the best minds of our generation to building better algorithms for keeping people glued to their phones. Hard tech is hard, and it takes real capital and real will to do it. But it can be done. The Manhattan Project was hard, going to the moon was hard, and we did both. He was equally candid about nuclear's image problem. Forty years of Homer Simpson falling asleep at a control panel, dropping plutonium rods into the sewer, has been a PR disaster for an industry that did not deserve it. The new generation of reactors bear no resemblance to Chernobyl. They are designed so that the physics itself prevents a meltdown, without anyone needing to press a button. Texas alone faces a shortfall of over 400 gigawatts just for data centres. The demand is real, the technology exists, and the regulatory environment is finally moving in the right direction. What the industry needs now is for the right people to point their energy at the right problems.

An investment in the WisdomTree Uranium and Nuclear Energy UCITS ETF may be subject to significant volatility and involves the risk of capital loss. The Fund's focus on the uranium and nuclear energy sector means its performance may be particularly affected by changes in commodity prices, regulation, government policy, technological developments and geopolitical events. Please refer to the KID and Prospectus for full details of the risks associated with an investment in the Fund.

1 Positron emission tomography

IMPORTANT INFORMATION

Marketing/communications/issued/in the European Economic Area ("EEA")/& Switzerland: This/document/has been issued/and approved/by WisdomTree Ireland Limited, which is authorised and regulated by the Central Bank of Ireland.

Marketing/communications/issued/in/jurisdictions/outside of the EEA, except Switzerland: This/document/has been issued/and approved/by WisdomTree UK Limited/or Atlantic House Investments Limited, which/are both/authorised and regulated by the United Kingdom Financial Conduct Authority.

WisdomTree Ireland Limited,/WisdomTree UK/Limited/and Atlantic House Investments Limited/are referred to as "WisdomTree" (as applicable)/throughout./Our Conflicts of Interest Policy and Inventory are available on request.

This marketing communication is intended for all investors; however, the WisdomTree products described in this document and related materials may be restricted in certain/jurisdictions/and may only be available to/particular categories/of investors/in accordance with/applicable laws and regulations. Where a product is not authorised or its distribution is restricted in your/jurisdiction, it is the responsibility of any person or entity in possession of this information to inform themselves of, and/comply with, all relevant restrictions. Before making any investment, investors should seek/appropriate legal, regulatory, tax and investment advice to assess the suitability and implications of investing in these products. Information about WisdomTree products is available at wisdomtree.eu. WisdomTree does not offer investment advice tailored to individual circumstances. Past performance is not a reliable indicator of future performance. Any historical performance included in this document may be based on back testing. Back testing is the process of evaluating an investment strategy by applying it to historical data to simulate what the performance of such strategy would have been. Back tested performance is purely hypothetical and is provided in this document solely for informational purposes. Back tested data does not/represent/actual performance and should not be interpreted as/an indication/of actual or future performance. The value of any investment may be affected by exchange rate movements. Any decision to invest should be based on the information contained in the/appropriate prospectus/and after seeking independent investment,/tax/and legal advice. The content of this document/does not constitute/investment advice nor an offer for sale nor a solicitation of an offer to buy any product or make any investment.

This marketing communication should be read in conjunction with/the relevant WisdomTree products' Prospectus, Key Investor Information Document ("KIID"),/Key Information Document ("PRIIPS/KID")/as relevant./In particular,/investors should carefully read the specific risks detailed under the section entitled/'Risk and Reward Profile' in/the/KIID,/'What are the risks and what could I get in return?' in PRIIPs KID and under the section entitled 'Risk Factors' in the Prospectus of the Issuer for further details of risks associated with an investment in the product(s)/detailed herein./Further information/regarding/the WisdomTree exchange-traded product(s) detailed/herein, such as a detailed list of the underlying investments and the indicative net asset value, can be obtained by visiting the WisdomTree website at (www.wisdomtree.eu).

An investment in/WisdomTree/exchange-traded products ("ETPs")/is dependent on the performance of the underlying index, less costs, but it is not expected to match that performance precisely./An investment in/WisdomTree funds is dependent on the performance of the underlying/investments, less costs.

Both WisdomTree/ETPs/and funds/involve numerous risks including among others, general market risks relating to/any/relevant underlying index, credit risks on the provider of index swaps utilised in ETPs, exchange rate risks, interest rate risks, inflationary risks, liquidity risks, derivatives risk/and legal and regulatory risks.

The information contained/in this document is not, and under no circumstances is to be construed as, an advertisement or any other step in furtherance of a public offering of shares in the United States or any province or territory thereof, where none of the/issuers or their products are authorised or registered for distribution and where no prospectus of any of the/issuers has been filed with any securities commission or regulatory authority. No document or information/in this document should be taken,/transmitted/or distributed (directly or indirectly) into the United States. None of the/issuers, nor any securities issued by them, have been or will be registered under the United States Securities Act of 1933 or the Investment Company Act of 1940 or qualified under any applicable state securities statutes.

This document may/contain/independent market commentary prepared by WisdomTree based on publicly available information. Although WisdomTree endeavours to ensure the accuracy of the content in this document, WisdomTree does not/warrant/or guarantee its accuracy or correctness. Any/third party/data providers used to source the information in this document make no warranties or representation of any kind relating to such data. Where WisdomTree has expressed its own opinions related to product or market activity, these views may change. Neither WisdomTree, nor any affiliate, nor any of their respective officers, directors, partners, or employees accepts any liability whatsoever for any direct or consequential loss arising from any use of this document or its contents.

This document may/contain/forward looking statements including statements/regarding/our belief or current expectations with regards to the performance of certain assets classes and/or sectors. Forward looking statements are subject to certain risks,/uncertainties/and assumptions. There can be no assurance that such statements will be/accurate/and actual results could differ materially from those/anticipated/in such statements./WisdomTree strongly recommends that you do not place undue reliance on these forward-looking statements.

WisdomTree Issuer ICAV

Certain funds referred to in this document are issued by WisdomTree Issuer ICAV ("WT Issuer"). WT Issuer is an open-ended, umbrella-type Irish Collective Asset-management Vehicle with segregated liability between sub-funds and is authorised by the Central Bank of Ireland ("CBI") as an Undertaking for Collective Investment in Transferable Securities ("UCITS") under Irish law. Each fund is represented by a separate class of shares (the "Shares") issued by WT Issuer.

The Fund is described in a Key Information Document (KID) or Key Investor Information Document (KIID) for UK investors, and the prospectus of WT Issuer ("WT Prospectus"). A copy of the WT Prospectus and the KID / KIID is available, for EEA/UK only, in English at www.wisdomtree.eu. Where required under national rules, the KID will also be available in the local language of the relevant EEA Member State. Investors should read the WT Prospectus before investing and should refer to the section of the WT Prospectus entitled 'Risk Factors' for further details of risks associated with an investment in the Shares.

The summary of investor rights associated with an investment in the fund is available in English on WisdomTree Europe's website. WisdomTree Management Limited may decide to terminate the arrangements made for the marketing of its collective investment undertakings. In such circumstances, shareholders in the affected EEA Member State will be notified of this decision and will be provided with the opportunity to redeem their shareholding in the fund free of any charges or deductions for at least 30 working days from the date of such notification.

For Investors in Switzerland:

This document/constitutes/an advertisement of the financial product(s) mentioned/herein.

The prospectus (in English only), a summary of the WIXL prospectus (in German, French and Italian) and the key investor information documents (KID) (in German, French and Italian) are available from WisdomTree's website: https://www.wisdomtree.eu/en-ch/resource-library/prospectus-and-regulatory-reports

For WisdomTree UCITS products only: the representative and paying agent of the ETPs in Switzerland is Société Générale Paris, Zurich Branch,/Talacker/50, PO Box 5070, 8021 Zurich, Switzerland. The prospectus, the key investor information documents (KIID), the articles of association and the annual and semi-annual reports of the sub-funds are available free of charge from the representative and paying agent. As regards distribution in Switzerland, the place of/jurisdiction/and performance is at the registered seat of the representative and paying agent. Some of the sub-funds referred to in this document may not have

been registered with the Swiss Financial Market Supervisory Authority (“FINMA”). In Switzerland, such sub-funds that have not been registered with FINMA may only be available to Qualified Investors.

FOR INVESTORS IN FRANCE:

Further information regarding the WisdomTree exchange-traded product(s) detailed herein, such as a detailed list of the underlying investments and the indicative net asset value, can be obtained by visiting the WisdomTree website at (www.wisdomtree.eu).

The product is intended for retail investors who: (i) can withstand capital loss, are not seeking to preserve capital and are not seeking a capital guarantee; (ii) have specific knowledge or experience in investing in similar products and in the financial markets; and (iii) are looking for a product that provides exposure to the performance of the underlying asset(s) and have an investment horizon in line with the recommended holding period indicated in the KID.

In addition, the indicative net asset value is shown on the Reuters and Bloomberg pages of the product and may also be mentioned on the websites of the product's listing venues.

Units in a listed exchange-traded product purchased on the secondary market generally cannot be sold directly back to the listed exchange-traded product. For investors who are not authorised participants, the purchase and sale of units must be done on a secondary market with the help of an intermediary (e.g., a broker), and may therefore be subject to additional fees and taxes. In addition, it is possible that investors may pay more than the current net asset value when purchasing units and receive less than the current net asset value when selling them.

Investors should carefully read the specific risks detailed under the section entitled ‘What are the risks and what could I get in return?’ in the Key Information Document for Packaged Retail and Insurance-based Investment Products (PRIIPs KID) and under the section entitled ‘Risk Factors’ in the Prospectus of the Issuer for further details of risks associated with an investment in the product detailed herein.

Investors are advised that the prospectus is available in French and English.

This document is a promotional material relating to the financial product(s) mentioned herein. The prospectus and the Key Investor Information Document (KIID) are available on the WisdomTree website: https://www.wisdomtree.eu/resource-library/prospectus-and-regulatory-reports

The distribution of the Prospectus and the offering, sale and delivery of Shares in other jurisdictions may be restricted by law. WT Issuer is a UCITS governed by Irish legislation, and approved by the Central Bank of Ireland as UCITS compliant with European regulations although it may not have to comply with the same rules as those applicable to a similar product approved in France.

The Fund has been registered for marketing in France by the Financial Markets Authority (Autorité des Marchés Financiers) and may be distributed to investors in France. Copies of all documents (i.e. the Prospectus, any supplements or addenda thereto, the Key Information Document, the latest annual reports and the instrument of incorporation) are available in France, free of charge at the French centralizing agent,

Societe Generale at 29, Boulevard Haussmann, 75009, Paris, France. Any subscription for Shares of the Fund will be made on the basis of the terms of the prospectus and any supplements or addenda thereto.

Investors should note that, relative to the expectations of the Autorité des Marchés Financiers, this UCITS presents disproportionate communication on the consideration of non-financial criteria in its management.

For Investors in Malta: This document does not constitute or form part of any offer or invitation to the public to subscribe for or purchase shares in the Fund and shall not be construed as such and no person other than the person to whom this document has been addressed or delivered shall be eligible to subscribe for or purchase shares in the Fund. Shares in the Fund will not in any event be marketed to the public in Malta without the prior authorisation of the Maltese Financial Services Authority.

For Investors in Monaco: This communication is only intended for duly registered banks and/or licensed portfolio management companies in Monaco. This communication must not be sent to the public in Monaco.

For Investors in Israel:

Offering materials for the offering of the securities have not been filed with or approved or disapproved by the United States Securities and Exchange Commission or any other state or federal regulatory authority, nor has any such regulatory authority passed upon or endorsed the merits of this offering or passed upon the accuracy or completeness of any offering materials. Any representation to the contrary is unlawful. The products mentioned herein have not been approved by the Israel Securities Authority and will only be distributed to Israeli residents in a manner that will not constitute “an offer to the public” under sections 15 and 15a of the Israel Securities Law, 5728-1968 (“the Securities Law”) or section 25 of the Joint Investment Trusts Law, 5754-1994 (“the Joint Investment Trusts Law “), as applicable. The products are being offered to a limited number of investors (35 investors or fewer during any given 12 month period) and/or those categories of investors listed in the First Addendum (“the Addendum”) to the Securities Law, “Sophisticated Investors”) who in each case have provided written confirmation that they qualify as Sophisticated Investors, and that they are aware of the consequences of such designation and agree thereto; in all cases under circumstances that will fall within the private placement or other exemptions of the Joint Investment Trusts Law, the Securities Law and any applicable guidelines, pronouncements or rulings issued from time to time by the Israel Securities Authority.

This prospectus or this document may not be reproduced or used for any other purpose, nor be furnished to any other person other than those to whom copies have been sent. Any offeree who purchases a product is purchasing such product for its own benefit and account and not with the aim or intention of distributing or offering such product to other parties (other than, in the case of an offeree which is a Sophisticated Investor by virtue of it being a banking corporation, portfolio manager or member of the Tel-Aviv Stock Exchange, as defined in the Addendum, where such offeree is purchasing a product for another party which is a Sophisticated Investor).

Nothing in this document should be considered investment advice or investment marketing as defined in the Regulation of Investment Counselling, Investment Marketing and Portfolio Management Law, 5755-1995. Investors are encouraged to seek competent investment counselling from a locally licensed

investment counsel prior to making the investment. A recipient of this document may be required to provide confirmation that it is a Sophisticated Investor purchasing a product for its own account or, where applicable, for other Sophisticated Investors.